desonide and Eye-Diseases

Although there is a variety of animal models available, neither a single assay system nor the results of the various assays permit absolute protection of relative anti-inflammatory potency. Equally, current clinical dose titration studies, although more reliable, provide only gross estimates of therapeutic potency when conducted in certain clinical situations in a double-blind randomized fashion. This paper delineated clinical means to titrate more objectively and accurately therapeutic potency in the patient. Moreover, it has submitted considerations as to how to assess therapeutic anti-inflammatory activity in the complex multi-component process of inflammation accompanying most dermatologic diseases that eventually may permit titration of specific anti-inflammatory compounds on certain tissue components of the inflammatory process.

Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Clinical Trials as Topic; Desonide; Disease Models, Animal; Drug Evaluation; Drug Evaluation, Preclinical; Edema; Eye Diseases; Female; Fibroblasts; Glucocorticoids; Humans; Inflammation; Mitosis; Psoriasis; Rabbits; Triamcinolone Acetonide; Vagina; Vasoconstrictor Agents